Literature DB >> 19523121

Comparative effectiveness research and evidence-based health policy: experience from four countries.

Kalipso Chalkidou1, Sean Tunis, Ruth Lopert, Lise Rochaix, Peter T Sawicki, Mona Nasser, Bertrand Xerri.   

Abstract

CONTEXT: The discussion about improving the efficiency, quality, and long-term sustainability of the U.S. health care system is increasingly focusing on the need to provide better evidence for decision making through comparative effectiveness research (CER). In recent years, several other countries have established agencies to evaluate health technologies and broader management strategies to inform health care policy decisions. This article reviews experiences from Britain, France, Australia, and Germany.
METHODS: This article draws on the experience of senior technical and administrative staff in setting up and running the CER entities studied. Besides reviewing the agencies' websites, legal framework documents, and informal interviews with key stakeholders, this analysis was informed by a workshop bringing together U.S. and international experts.
FINDINGS: This article builds a matrix of features identified from the international models studied that offer insights into near-term decisions about the location, design, and function of a U.S.-based CER entity. While each country has developed a CER capacity unique to its health system, elements such as the inclusiveness of relevant stakeholders, transparency in operation, independence of the central government and other interests, and adaptability to a changing environment are prerequisites for these entities' successful operation.
CONCLUSIONS: While the CER entities evolved separately and have different responsibilities, they have adopted a set of core structural, technical, and procedural principles, including mechanisms for engaging with stakeholders, governance and oversight arrangements, and explicit methodologies for analyzing evidence, to ensure a high-quality product that is relevant to their system.

Mesh:

Year:  2009        PMID: 19523121      PMCID: PMC2881450          DOI: 10.1111/j.1468-0009.2009.00560.x

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  15 in total

1.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

2.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

3.  Prices and availability of biopharmaceuticals: an international comparison.

Authors:  Patricia M Danzon; Michael F Furukawa
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Developing a center for comparative effectiveness information.

Authors:  Gail R Wilensky
Journal:  Health Aff (Millwood)       Date:  2006-11-07       Impact factor: 6.301

5.  Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States.

Authors:  Elizabeth E Roughead; Ruth Lopert; Lloyd Norman Sansom
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

6.  Satisfaction guaranteed--"payment by results" for biologic agents.

Authors:  Alan M Garber; Mark B McClellan
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

7.  Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al.

Authors:  Sean R Tunis; Kalipso Chalkidou
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

Review 8.  Health literacy and patient information: developing the methodology for a national evidence-based health website.

Authors:  Hilda Bastian
Journal:  Patient Educ Couns       Date:  2008-10-28

9.  Cost-effectiveness information: yes, it's important, but keep it separate, please!

Authors:  Gail R Wilensky
Journal:  Ann Intern Med       Date:  2008-05-15       Impact factor: 25.391

10.  A menu without prices.

Authors:  Alan M Garber
Journal:  Ann Intern Med       Date:  2008-05-15       Impact factor: 25.391

View more
  28 in total

Review 1.  Delayed assessment and eager adoption of laparoscopic cholecystectomy: implications for developing surgical technologies.

Authors:  Alexander C Allori; I Michael Leitman; Elizabeth Heitman
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

Review 2.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  EBM, HTA, and CER: clearing the confusion.

Authors:  Bryan R Luce; Michael Drummond; Bengt Jönsson; Peter J Neumann; J Sanford Schwartz; Uwe Siebert; Sean D Sullivan
Journal:  Milbank Q       Date:  2010-06       Impact factor: 4.911

5.  Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.

Authors:  James D Neaton; Abdel Babiker; Mark Bohnhorst; Janet Darbyshire; Eileen Denning; Arnie Frishman; Jesper Grarup; Gregg Larson; Jens Lundgren
Journal:  Clin Trials       Date:  2010-08-20       Impact factor: 2.486

6.  Taking stock of the ethical foundations of international health research: pragmatic lessons from the IU-Moi Academic Research Ethics Partnership.

Authors:  Eric M Meslin; Edwin Were; David Ayuku
Journal:  J Gen Intern Med       Date:  2013-09       Impact factor: 5.128

Review 7.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493

Review 8.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

9.  Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.

Authors:  Patricia A Deverka; Danielle C Lavallee; Priyanka J Desai; Joanne Armstrong; Mark Gorman; Leah Hole-Curry; James O'Leary; B W Ruffner; John Watkins; David L Veenstra; Laurence H Baker; Joseph M Unger; Scott D Ramsey
Journal:  J Comp Eff Res       Date:  2012-07       Impact factor: 1.744

10.  Efficacy of Jian'ganle () versus Hugan Pian (), glucuronolactone and reduced glutathione in prevention of antituberculosis drug-induced liver injury.

Authors:  Quan Zhang; Fang-Ying Zhong; Meng Wu; Xin-Ping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.